<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part7">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>7</PartID>
        <PartNumber>Part VI</PartNumber>
        <PartSequenceNumber>7</PartSequenceNumber>
        <PartTitle>Prevention</PartTitle>
        <PartChapterCount>3</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap33" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>33</ChapterID>
          <ChapterNumber>Chapter 33</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_33</ChapterDOI>
          <ChapterSequenceNumber>33</ChapterSequenceNumber>
          <ChapterTitle Language="En">Inflammation as a Target in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>375</ChapterFirstPage>
          <ChapterLastPage>386</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterContext>
            <PartID>7</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_33" CorrespondingAffiliationID="Aff1_33">
              <AuthorName DisplayOrder="Western">
                <GivenName>Marshall</GivenName>
                <GivenName>Scott</GivenName>
                <FamilyName>Lucia</FamilyName>
              </AuthorName>
              <Contact>
                <Email>scott.lucia@ucdenver.edu</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>James</GivenName>
                <GivenName>R.</GivenName>
                <FamilyName>Lambert</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Elizabeth</GivenName>
                <GivenName>A.</GivenName>
                <FamilyName>Platz</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Angelo</GivenName>
                <GivenName>M.</GivenName>
                <Particle>De</Particle>
                <FamilyName>Marzo</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_33">
              <OrgDivision>Department of Pathology</OrgDivision>
              <OrgName>University of Colorado</OrgName>
              <OrgAddress>
                <City>Denver, Aurora</City>
                <State>CO</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_33" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Epidemiological studies have implicated chronic infections and inflammation as major risk factors for a variety of human cancers. Emerging evidence suggests that chronic inflammation is important for the development of prostate cancer and foci of inflammation (i.e., lymphocytes and macrophages) and is extremely common in the prostate. Multiple mechanisms have been investigated in studies examining the role of inflammation in prostate cancer initiation and development. In this chapter, we review the current state of thinking on the causes of prostatic inflammation, inflammatory genes potentially involved in prostatic inflammation and carcinogenesis, and the role of inflammation in the development of prostate cancer. An understanding of the role of chronic inflammation in the development of prostate cancer will provide new therapeutic strategies to combat the disease.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Carcinogenesis</Keyword>
            <Keyword>Chemoprevention</Keyword>
            <Keyword>Chemotherapy</Keyword>
            <Keyword>Cytokines</Keyword>
            <Keyword>Inflammation</Keyword>
            <Keyword>Oxidative stress</Keyword>
            <Keyword>Prostate cancer</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Para TextBreak="No">It is estimated that 20% of all human malignancies, including those of the colon, liver, stomach, bladder, cervix, and lung, result from chronic inflammation and/or chronic infections [<CitationRef CitationID="CR1_33">1</CitationRef>]. Although not yet proven, epidemiologic and histopathologic evidence is accumulating to incriminate chronic inflammation in the pathogenesis of prostate cancer. As the molecular pathways that orchestrate inflammatory processes become better defined, so do their potential roles in carcinogenesis. Inflammation due to tissue injury by infectious agents or other stimuli serves in the eradication of pathogens, clearing of debris, epithelial regeneration, stromal remodeling, and vascularization to heal the wound and restore function of the tissue. Once the repair is completed, the inflammatory reaction typically subsides. However, when inflammation becomes prolonged or unrelenting, these same processes may provide the critical ingredients for the development and progression of cancer, particularly in situations where epithelial mutagenesis has occurred.</Para>
          <Section1 ID="Sec1">
            <Heading>Chronic Inflammation of the Prostate</Heading>
            <Para TextBreak="No">Areas of inflammation are extremely common in the prostate, with studies reporting a prevalence of &gt;95% in resection specimens particularly involving the peripheral zone of the prostate where prostate cancer typically occurs [<CitationRef CitationID="CR2_33">2</CitationRef>–<CitationRef CitationID="CR4_33">4</CitationRef>]. Macrophages, T-cells and B-cells, characteristically present even in normal prostate [<CitationRef CitationID="CR2_33">2</CitationRef>], are increased in the aged and hyperplastic prostate [<CitationRef CitationID="CR3_33">3</CitationRef>–<CitationRef CitationID="CR5_33">5</CitationRef>]. The majority (70–80%) of lymphocytes are CD3+ T lymphocytes, &gt;90% of which express <Emphasis Type="Italic">αβ</Emphasis> T-cell receptor (TCR) [<CitationRef CitationID="CR5_33">5</CitationRef>–<CitationRef CitationID="CR8_33">8</CitationRef>]. A small percentage (&lt;5%) express γ<Emphasis Type="Italic">δ</Emphasis> TCR that respond to nonconventional phosphoantigens and demonstrate antitumor cytotoxic activity, although these cells may be present in higher numbers in cancerous tissues [<CitationRef CitationID="CR9_33">9</CitationRef>]. Both type 1 (Th1) and type 2 (Th2) immune responses, defined by differential cytokine production, have been found in hyperplastic tissues [<CitationRef CitationID="CR10_33">10</CitationRef>].</Para>
            <Para TextBreak="No">Inflammation is often found to involve areas of focal prostatic atrophy [<CitationRef CitationID="CR4_33">4</CitationRef>, <CitationRef CitationID="CR11_33">11</CitationRef>]. A spectrum of focal atrophic lesions that are associated with variable degrees of chronic inflammation have been described on a histological basis and grouped under the term proliferative inflammatory atrophy (PIA), with the recognition that many of these lesions have demonstrated increased proliferation and therefore may be a form of repair [<CitationRef CitationID="CR11_33">11</CitationRef>, <CitationRef CitationID="CR12_33">12</CitationRef>]. Like prostate cancer, PIA occurs predominantly in the peripheral zone of the prostate (as opposed to the more centrally-located transition zone where benign hyperplasia tends to occur) and increases in frequency with advancing age [<CitationRef CitationID="CR4_33">4</CitationRef>, <CitationRef CitationID="CR11_33">11</CitationRef>, <CitationRef CitationID="CR12_33">12</CitationRef>]. PIA lesions have also been suggested as representing early events in prostatic carcinogenesis [<CitationRef CitationID="CR4_33">4</CitationRef>, <CitationRef CitationID="CR11_33">11</CitationRef>, <CitationRef CitationID="CR13_33">13</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Possible Causes of Prostatic Inflammation</Heading>
            <Para TextBreak="No">Although chronic inflammation in the prostate is a common occurrence, the cause of prostatic inflammation is unknown. Infectious, hormonal, dietary, and/or physico-chemical factors have the potential to produce a chronic inflammatory process in the prostate. It is also possible that once one or more of these insults triggers an initial inflammatory response, it could lead to the development of an autoimmune reaction to prostatic antigens that continues well after the inciting agent is cleared.</Para>
            <Section2 ID="Sec3">
              <Heading>Infectious Agents</Heading>
              <Para TextBreak="No">A variety of bacteria (sexually and nonsexually transmitted) and viruses have been detected in the prostate (reviewed in [<CitationRef CitationID="CR4_33">4</CitationRef>]); some of these agents may reach the prostate and elicit an inflammatory response [<CitationRef CitationID="CR14_33">14</CitationRef>]. Although generally felt to be acute or self-limited in condition, the potential for infections to become chronic or unrelenting is not known. Certainly, asymptomatic infections can occur. Several small scale case–control epidemiologic studies have observed mildly increased risks for prostate cancer in men with histories of sexually-transmitted infections [<CitationRef CitationID="CR15_33">15</CitationRef>, <CitationRef CitationID="CR16_33">16</CitationRef>]. Meta-analyses calculated odds ratio of 1.4–1.5 for men with a history of any sexually-transmitted infection, 1.4 for a history of gonorrhea, and 1.6–2.3 for a history of syphilis [<CitationRef CitationID="CR15_33">15</CitationRef>, <CitationRef CitationID="CR16_33">16</CitationRef>], although in these studies recall bias cannot be excluded. A higher risk of prostate cancer was also identified in a prospective study in men who carried antibodies against the protozoan <Emphasis Type="Italic">Trichomonas vaginalis</Emphasis> [<CitationRef CitationID="CR17_33">17</CitationRef>]. A number of viruses including herpes viruses, cytomegalovirus, and human papilloma virus may also infect the prostate; however, little evidence exists to support a causal role in prostate cancer (reviewed in [<CitationRef CitationID="CR18_33">18</CitationRef>]). Whereas these studies have focused on classical pathogens, it is also possible that an as yet unidentified microbe or virus may be involved in the pathogenesis of prostate cancer. Recently, a new γ retrovirus, xenotropic murine leukemia-related virus (XMRV) was detected in prostate cancer specimens using a DNA microarray-based analysis [<CitationRef CitationID="CR19_33">19</CitationRef>]. The virus was detected primarily in men with a specific germline mutation of RNASEL (see below), the gene that encodes for the antiviral enzyme RNaseL, suggesting that prolonged infection in the prostate may be a result of genetic predisposition. While intriguing, it is yet unknown whether this virus might also be found in the prostates of men without a diagnosis of prostate cancer. Although all of these results suggest that an infectious cause may be potentially responsible for a certain proportion of prostate cancer, this may not be necessarily due to direct oncogenic actions of an infectious agent. Prolonged infection could trigger an inflammatory reaction that persists despite clearance of the organism by the unmasking of self antigens in an autoimmune manner. In support of this, T-cell responses against histone peptides and prostate-specific antigen (PSA) have been detected in the prostate [<CitationRef CitationID="CR20_33">20</CitationRef>, <CitationRef CitationID="CR21_33">21</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>Hormones</Heading>
              <Para TextBreak="No">It has long been recognized that androgens are involved in prostatic carcinogenesis [<CitationRef CitationID="CR22_33">22</CitationRef>], forming the basis for androgen ablation therapy for advanced prostate cancer. In rodent models, estrogens can potentiate prostatic carcinogenesis when combined with androgen [<CitationRef CitationID="CR23_33">23</CitationRef>]. Estrogens in the presence of androgen causes increased prostatic inflammation in animal models [<CitationRef CitationID="CR24_33">24</CitationRef>]. Although the mechanism by which this occurs is unclear, it may involve upregulation of nuclear factor kappa B (NF-<Emphasis Type="Italic">κ</Emphasis>B) [<CitationRef CitationID="CR24_33">24</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Dietary Factors</Heading>
              <Para TextBreak="No">The potential for cell and DNA damage by reactive oxygen and/or nitrogen species elaborated during an immune response to infectious agents or other elicitors may be countered by antioxidants. In some studies, higher exposure to lycopene (a free-radical scavenger), selenium (an element required for activity of an antioxidant enzyme), and vitamin E, at least in smokers, have each been observed to be inversely associated with prostate cancer risk [<CitationRef CitationID="CR25_33">25</CitationRef>–<CitationRef CitationID="CR27_33">27</CitationRef>].</Para>
              <Para TextBreak="No">Epidemiological studies also suggest an association between consumption of animal fat and red and processed meat and prostate cancer incidence and mortality [<CitationRef CitationID="CR28_33">28</CitationRef>]. It is hypothesized that certain dietary compounds are selectively taken up in the prostate, thereby acting as either direct carcinogens (initiators and/or promoters) or indirectly by stimulating a localized inflammatory reaction. For example, the heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), is a carcinogen formed during the cooking of meats at high temperature [<CitationRef CitationID="CR28_33">28</CitationRef>]. Administration of PhIP to laboratory rats produces carcinomas of the ventral prostate [<CitationRef CitationID="CR29_33">29</CitationRef>]. Interestingly, despite observed increases in mutation frequency in all four lobes of the rat prostate upon PhIP administration (initiating activity), carcinomas only developed in the ventral prostate where there was also a ventral lobe-specific increase in inflammatory cells, particularly macrophages and mast cells associated with epithelial injury and atrophy analogous to PIA (promoting activity) [<CitationRef CitationID="CR29_33">29</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Prostatic and Urinary Factors</Heading>
              <Para TextBreak="No">The prostatic epithelium produces a variety of factors that can stimulate or inhibit inflammatory reactions. For example, PSA, a major serine protease produced by prostatic epithelial cells, has been shown to stimulate a T-cell immune reaction in patients with prostatitis/pelvic pain syndrome [<CitationRef CitationID="CR21_33">21</CitationRef>]. Inspissated prostatic secretions, or corpora amylacea, may erode into the stroma where they often produce a profound chronic inflammatory reaction [<CitationRef CitationID="CR4_33">4</CitationRef>]. Increased ejaculation frequency has been associated with a lower risk for prostate cancer [<CitationRef CitationID="CR30_33">30</CitationRef>]. Functional purging or “flushing” of the prostate may reduce epithelial contact with carcinogens that are concentrated in urine or prostatic secretions, reduce the likelihood of corpora amylacea forming, reduce risk of infection, and stimulate healthy epithelial turnover. Obstruction or urine reflux may lead to increased prostatic inflammation through chemical irritation, increased exposure to infectious agents, or pressure-induced epithelial injury with subsequent production of inflammatory cytokines.</Para>
              <Para TextBreak="No">Functional mature prostatic epithelium also produces potential inhibitors of inflammation including transforming growth factor-beta (TGF-<Emphasis Type="Italic">β</Emphasis>) and prostate-derived factor (PDF) (aka macrophage inhibitory cytokine, MIC-1). It is therefore plausible that in normal prostate, there is a balance between pro-inflammatory and anti-inflammatory processes. When this balance is perturbed either by an increase in pro-inflammatory or a decrease in anti-inflammatory factors or both by one or more dietary, infectious, hormonal or physicochemical insults, a chronic inflammatory condition occurs. Progressive damage to the prostatic tissues may then “fuel the fire” to produce an autoimmune reaction forming the “primordial soup” of eventual carcinogenesis.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Inflammatory Genes in Prostate Cancer</Heading>
            <Para TextBreak="No">Heredity plays an important role in prostatic carcinogenesis with an estimated one-quarter of all prostate cancer occurring in family clusters [<CitationRef CitationID="CR31_33">31</CitationRef>–<CitationRef CitationID="CR33_33">33</CitationRef>]. Several of the genes associated with prostate cancer risk encode products that play critical roles in inflammatory pathways. Pedigree analysis has identified three genes, RNASEL, PDF, and MSR1, which are linked to prostate cancer [<CitationRef CitationID="CR34_33">34</CitationRef>–<CitationRef CitationID="CR36_33">36</CitationRef>]. Variants in genes encoding other components of the immune response, including interleukins (IL-6, IL-8, IL-10) and toll-like receptors (TLRs) have also been evaluated for their associations with prostate cancer in case–control studies [<CitationRef CitationID="CR37_33">37</CitationRef>].</Para>
            <Section2 ID="Sec8">
              <Heading>RNASEL</Heading>
              <Para TextBreak="No">The hereditary prostate cancer 1 (HPC1) region on chromosome 1 was the first susceptibility region identified in familial prostate cancer [<CitationRef CitationID="CR34_33">34</CitationRef>]. Subsequent studies demonstrated that the HPC1 locus harbors the gene encoding ribonuclease L (RNASEL). RNaseL functions in the innate immune system by degrading single-stranded viral RNAs. Sustained activation of RNaseL leads to a mitochondrial-mediated pathway of apoptosis that eliminates virally infected cells [<CitationRef CitationID="CR38_33">38</CitationRef>]. Mutations in RNASEL lead to production of RNaseL with impaired ability to promote apoptosis of virally infected cells. Several studies examining the role of RNASEL as a prostate cancer susceptibility gene have been reported. While some studies demonstrate confirmatory evidence, others do not [<CitationRef CitationID="CR39_33">39</CitationRef>], suggesting either population differences or environmental factors may modulate the role of RNASEL in prostatic carcinogenesis.</Para>
              <Para TextBreak="No">A common genetic variant in RNASEL resulting in reduced enzymatic activity of RNaseL (R462Q) has been implicated in up to 13% of prostate cancers. The XMRV virus was primarily detected in individuals homozygous for this mutation [<CitationRef CitationID="CR19_33">19</CitationRef>]. Activation of RNaseL in DU145 human prostate cancer cells induced the putative pro-apoptotic suppressor of prostate cancer, PDF.</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>Prostate-Derived Factor</Heading>
              <Para TextBreak="No">PDF is a secretory protein with homology to members of the TGF-<Emphasis Type="Italic">β</Emphasis> superfamily and has previously been identified as nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1) and MIC-1 [<CitationRef CitationID="CR40_33">40</CitationRef>, <CitationRef CitationID="CR41_33">41</CitationRef>]. PDF was first identified as a gene involved in macrophage activation, and its expression is induced by NSAIDs in human colorectal carcinoma cells [<CitationRef CitationID="CR40_33">40</CitationRef>, <CitationRef CitationID="CR41_33">41</CitationRef>]. Together, these findings support a role for PDF in inflammatory processes and may provide insight into the proposed tumor-suppressive activities of PDF.</Para>
              <Para TextBreak="No">PDF mRNA is highly expressed in human prostate epithelium suggesting a role in prostate homeostasis, and several studies have shown that PDF inhibits prostate cancer cell growth and induces apoptosis [<CitationRef CitationID="CR42_33">42</CitationRef>–<CitationRef CitationID="CR44_33">44</CitationRef>]. PDF resides on chromosome 19 in a region identified as a susceptibility locus in genome-wide studies on prostate cancer incidence [<CitationRef CitationID="CR35_33">35</CitationRef>]. Additionally, a genetic polymorphism in PDF has been described that changes the basic amino acid histidine (H) to aspartic acid (D) at position 6 of the mature PDF protein [<CitationRef CitationID="CR45_33">45</CitationRef>]. This change has been associated with a lower risk of sporadic and familial prostate cancer [<CitationRef CitationID="CR35_33">35</CitationRef>]. However, a similar study found the H6D polymorphism to be only marginally associated with a lower risk of prostate cancer development, but it was associated with increased risk of progression once the tumor had been established [<CitationRef CitationID="CR46_33">46</CitationRef>]. Thus, the role of PDF in prostate cancer initiation and progression is not clear.</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>Macrophage Scavenger Receptor (MSR1)</Heading>
              <Para TextBreak="No">Macrophage scavenger receptor (MSR1) is a candidate prostate cancer susceptibility gene identified through linkage analysis of HPC [<CitationRef CitationID="CR36_33">36</CitationRef>]. The MSR1 gene encodes a homotrimeric class A receptor that is primarily expressed in macrophages. It is termed a “scavenger receptor” due to the diverse array of ligands it binds including gram-positive and gram-negative bacteria and lipoproteins. MSR1 action has been linked to a variety of normal and pathologic processes including inflammation and immunity. Mice defective for MSR1 function are more susceptible to bacterial infection suggesting an anti-inflammatory role for MSR1 [<CitationRef CitationID="CR47_33">47</CitationRef>, <CitationRef CitationID="CR48_33">48</CitationRef>].</Para>
              <Para TextBreak="No">Although a number of studies have demonstrated an increased frequency of MSR1 mutations in men with prostate cancer, studies on the role of these variants and prostate cancer risk have yielded inconsistent results. Interestingly, MSR1 mutations have been identified to have a more reproducible effect on prostate cancer risk in African-American men [<CitationRef CitationID="CR49_33">49</CitationRef>]. Although studies to date have not defined MSR1 as a major prostate cancer gene per se, they do suggest that MSR1 may, in combination with environmental cues such as pathogen infection, modify prostate cancer risk.</Para>
            </Section2>
            <Section2 ID="Sec11">
              <Heading>Interleukins</Heading>
              <Para TextBreak="No">Case–control studies have evaluated sequence variants in the genes encoding IL-8 and IL-10 among others and prostate cancer risk with mixed results. IL-8 is a pro-inflammatory cytokine often found at elevated levels in the semen of men with chronic prostatitis [<CitationRef CitationID="CR50_33">50</CitationRef>] and is also associated with prostatic angiogenesis [<CitationRef CitationID="CR51_33">51</CitationRef>]. IL-10 is considered an anti-inflammatory cytokine with immunoregulatory functions including downregulation of Th1. Further work is necessary to evaluate the hypothesis that sequence variants in IL-8 and/or IL-10 are involved in prostatic inflammation and development of prostate cancer.</Para>
            </Section2>
            <Section2 ID="Sec12">
              <Heading>Toll-Like Receptors</Heading>
              <Para TextBreak="No">TLRs are transmembrane proteins expressed by cells of the innate immune system. TLRs recognize invading pathogens and activate signaling pathways leading to inflammatory immune responses that clear the infection. In humans, the TLR family includes eleven proteins (TLR1–TLR11). Different TLRs serve as receptors for a wide variety of ligands including bacterial cell-wall components, viral RNA or immunomodulatory compounds.</Para>
              <Para TextBreak="No">Several studies have explored the possible connection between TLR signaling and prostate cancer. Sequence variants in several TLR genes including TLR-4 and the TLR-1–6–10 cluster have been linked to prostate cancer risk [<CitationRef CitationID="CR52_33">52</CitationRef>, <CitationRef CitationID="CR53_33">53</CitationRef>]. Further investigations are required to understand the biological consequences of TLR signaling and prostate cancer risk. However, because TLR signaling is so critically related to innate immunity, it is intriguing to speculate a central role for TLR-signaling in prostatic inflammation and prostate cancer development.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec13">
            <Heading>Chronic Inflammation in the Development of Prostate Cancer</Heading>
            <Para TextBreak="No">The “immune surveillance” theory has long held that inflammation is a consequence of the host response against a cancer rather than a cause [<CitationRef CitationID="CR54_33">54</CitationRef>]. However, recent evidence suggests that the cytokine environment of tumor-associated inflammatory cells actually suppresses cell-mediated antitumor immune surveillance activities [<CitationRef CitationID="CR55_33">55</CitationRef>, <CitationRef CitationID="CR56_33">56</CitationRef>]. Indeed, studies now suggest that longstanding inflammation through a number of interrelated mechanisms acting in a concerted fashion may serve to favor tumor growth and spread. These include the elaboration of cytokines and growth factors that favor tumor cell growth, generation of mutagenic reactive oxygen and nitrogen species (ROS and RNS), and induction of cyclooxygenase-2 and prostaglandin (PG) synthesis.</Para>
            <Section2 ID="Sec14">
              <Heading>Cytokines and Growth Factors</Heading>
              <Para TextBreak="No">Chronic inflammation produces an environment rich in cytokines and growth factors that govern cell-to-cell communication and may contribute to malignant progression [<CitationRef CitationID="CR57_33">57</CitationRef>]. Tumor necrosis factor-<Emphasis Type="Italic">α</Emphasis> (TNF-<Emphasis Type="Italic">α</Emphasis>), a pro-inflammatory cytokine produced predominantly by macrophages/monocytes upon exposure to a wide range of stimuli, has an important role in orchestrating inflammatory events, host responses to pathogens, and wound healing by inducing a cascade of other cytokines and growth factors such as COX-2, angiogenic factors, and matrix metalloproteins (MMPs) [<CitationRef CitationID="CR58_33">58</CitationRef>]. Production of TNF-<Emphasis Type="Italic">α</Emphasis> in cultured prostate cancer cells suppresses androgen receptor expression and may contribute to loss of androgen responsiveness [<CitationRef CitationID="CR59_33">59</CitationRef>]. TNF-<Emphasis Type="Italic">α</Emphasis> may also directly stimulate tumor cell proliferation through activation of NF-<Emphasis Type="Italic">κ</Emphasis>B [<CitationRef CitationID="CR60_33">60</CitationRef>]. The NF-<Emphasis Type="Italic">κ</Emphasis>B family of transcription factors includes key regulators of genes involved in cell growth and differentiation such as c-myc, cyclin-D1, and IL-6 and inhibitors of apoptosis such as Bcl-2 (Fig. <InternalRef RefID="Fig1">33.1</InternalRef>) [<CitationRef CitationID="CR61_33">61</CitationRef>]. NF-<Emphasis Type="Italic">κ</Emphasis>B may also regulate angiogenesis through modulation of vascular endothelial growth factor (VEGF) [<CitationRef CitationID="CR61_33">61</CitationRef>, <CitationRef CitationID="CR62_33">62</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 33.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Complex interaction between reactive oxygen species (ROS), reactive nitrogen species (RNS), nuclear factor kappa B (NF-<Emphasis Type="Italic">κ</Emphasis>B), cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), and cellular processes promoting tumorigenesis. <Emphasis Type="Italic">PGE2</Emphasis> prostaglandin E2</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO1_33">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_33_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
                     </Para>
              <Para TextBreak="No">VEGF stimulates endothelial proliferation, induces angiogenesis, regulates vascular permeability and is a key target for antiangiogenic chemotherapeutic agents [<CitationRef CitationID="CR63_33">63</CitationRef>, <CitationRef CitationID="CR64_33">64</CitationRef>]. Although VEGF expression is limited to basal cells in the normal prostate, it is also expressed in prostate cancer and prostatic intraepithelial neoplasia (PIN) [<CitationRef CitationID="CR65_33">65</CitationRef>]. In addition to NF-<Emphasis Type="Italic">κ</Emphasis>B, VEGF production is induced by prostaglandin E2 (PGE2) and TNF-<Emphasis Type="Italic">α</Emphasis>.</Para>
              <Para TextBreak="No">A variety of interleukins and chemokines produced by inflammatory cells during the inflammatory response may have the potential to stimulate tumor cell proliferation, survival, and metastasis. Interleukins such as IL-1 and IL-8 have been shown to stimulate growth of cancer cells in vitro [<CitationRef CitationID="CR66_33">66</CitationRef>, <CitationRef CitationID="CR67_33">67</CitationRef>]<Emphasis Type="Italic">.</Emphasis> IL-1 modulates the expression of MMPs that facilitate cell migration [<CitationRef CitationID="CR68_33">68</CitationRef>]. IL-8 is a potent inducer of angiogenesis [<CitationRef CitationID="CR69_33">69</CitationRef>]. Finally, CXC group chemokines, such as gro-<Emphasis Type="Italic">α</Emphasis> and CXC-12, may contribute to carcinogenesis by direct stimulation of tumor cell growth, regulation of angiogenesis, or aid in tumor cell chemotaxis [<CitationRef CitationID="CR68_33">68</CitationRef>, <CitationRef CitationID="CR70_33">70</CitationRef>, <CitationRef CitationID="CR71_33">71</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec15">
              <Heading>Oxidative Stress</Heading>
              <Para TextBreak="No">Condemning evidence implicating inflammation in prostate carcinogenesis comes from molecular changes that occur in inflamed benign prostatic tissues such as PIA. Epithelial cells in PIA overexpress the glutathione S-transferases (GST) GSTP1 and GSTA1, suggesting that PIA lesions are under oxidative stress, possibly in part due to reactive species generated during the inflammatory response [<CitationRef CitationID="CR11_33">11</CitationRef>, <CitationRef CitationID="CR72_33">72</CitationRef>]. Reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, are highly reactive intermediate by-products of oxidative metabolism. ROS are produced in relatively high quantities by activated macrophages in response to a variety of stimuli as part of the “respiratory burst.” ROS may also be produced in many cell types in response to inflammatory cytokines and during the metabolism of many known carcinogens [<CitationRef CitationID="CR73_33">73</CitationRef>]. Reactive nitrogen species (RNS) include nitric oxide (NO) and its reactive intermediates. NO is a gas with free-radical properties that has a number of diverse actions including neurotransmission, vasodilatation, induction of apoptosis, p53 regulation, and modulation of epithelial proliferation [<CitationRef CitationID="CR74_33">74</CitationRef>]. RNS are produced in relatively high quantities by inflammatory cells and most other cell types by the inducible form of the enzyme NO synthase (iNOS, NOS2) in response to stimulation with inflammatory cytokines, such as TNF-<Emphasis Type="Italic">α</Emphasis> and IL-1 [<CitationRef CitationID="CR75_33">75</CitationRef>].</Para>
              <Para TextBreak="No">ROS and RNS may contribute to carcinogenesis by damaging cellular lipids, proteins, and DNA (see Fig. <InternalRef RefID="Fig1">33.1</InternalRef>). For instance, ROS and RNS together form peroxynitrite that directly damages cellular lipids and proteins [<CitationRef CitationID="CR74_33">74</CitationRef>]. ROS are also directly mutagenic to DNA causing the formation of 8-hydroxyguanine (8-OHG) [<CitationRef CitationID="CR76_33">76</CitationRef>]. As a defense against such insults, ROS can be neutralized by intracellular antioxidants (e.g., vitamin E, carotenoids) and cellular enzymes (e.g., glutathione peroxidase, which requires selenium for activity and glutathione-S-transferases) [<CitationRef CitationID="CR77_33">77</CitationRef>]. Oxidative and nitrosative stress refers to an imbalance between the production of reactive intermediates and these antioxidant defenses. GSTP1 is the primary GST present in prostatic epithelial cells. It is responsible for inactivating oxidant carcinogens via conjugation to reduced glutathione [<CitationRef CitationID="CR77_33">77</CitationRef>]. Inactivation of the GSTP1 gene by CpG island methylation occurs in a very high proportion of prostate cancer and PIN specimens [<CitationRef CitationID="CR78_33">78</CitationRef>]. Other major antioxidant enzymes including copper-zinc superoxide dismutase, manganese superoxide dismutase, and catalase were also shown to have lower expression in PIN and prostate cancer compared to benign epithelium [<CitationRef CitationID="CR79_33">79</CitationRef>]. The transition of PIA lesions to prostate cancer may be supported by the observation that in tissues taken from men with prostate cancer, the proportion of methylated GSTP1 promoter region CpG sites is 0% in normal epithelium and BPH, approximately 6% in PIA, 70% in HGPIN, and over 90% in adenocarcinoma [<CitationRef CitationID="CR13_33">13</CitationRef>].</Para>
              <Para TextBreak="No">Measures of oxidative stress can be increased by androgens in human prostate cancer cell lines [<CitationRef CitationID="CR80_33">80</CitationRef>]. In situations of increased oxidative and/or nitrosative stress, progressive damage to epithelial cells leads to cell death triggering replacement by proliferation of resident progenitor cells. DNA synthesis in the presence of mutagenic reactive intermediates is thus at increased risk of mutagenesis. Damage to DNA repair enzymes via hydroxylation (ROS) or nitrosylation (RNS) may alter their activity, thereby exacerbating mutagenesis [<CitationRef CitationID="CR81_33">81</CitationRef>]. The cumulative result is an imbalance between the rate of mutagenesis and the ability to repair mutations (without error), allowing for their progressive accumulation [<CitationRef CitationID="CR82_33">82</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Cyclooxygenase-2</Heading>
              <Para TextBreak="No">Cyclooxygenase (COX) is a key enzyme in the synthesis of PGs and other eicosanoids from arachidonic acid (AA) and exists in two isoforms. COX-1 is constitutively expressed in many tissues, whereas COX-2 is not usually expressed or expressed at very low levels in epithelial tissues but is predominantly expressed by inflammatory cells such as macrophages. Oxidative stress can rapidly induce COX-2 in epithelial cells, either directly through lipid peroxidation [<CitationRef CitationID="CR83_33">83</CitationRef>] or indirectly through induction of NF-<Emphasis Type="Italic">κ</Emphasis>B (see Fig. <InternalRef RefID="Fig1">33.1</InternalRef>) [<CitationRef CitationID="CR84_33">84</CitationRef>]. COX-2 may also be induced by TNF-<Emphasis Type="Italic">α</Emphasis> and interleukin-1 produced by inflammatory cells [<CitationRef CitationID="CR85_33">85</CitationRef>]. Overexpression of COX-2 is associated with increased tumorigenesis in animal models and alterations in cellular adhesion and apoptosis in epithelial cells [<CitationRef CitationID="CR86_33">86</CitationRef>]. COX-2 stimulates angiogenesis in tumors by induction of PGE2 and VEGF [<CitationRef CitationID="CR87_33">87</CitationRef>]. Conversely, suppression of COX-2 inhibits angiogenesis and tumor growth [<CitationRef CitationID="CR87_33">87</CitationRef>]. While studies have shown that COX-2 may or may not be elevated in prostate cancers per se, benign tissues that are inflamed such as PIA show elevated COX-2 expression [<CitationRef CitationID="CR88_33">88</CitationRef>]. In vitro studies showed that COX-2 inhibitors decreased growth and increased apoptosis in prostate cancer cell lines [<CitationRef CitationID="CR89_33">89</CitationRef>]. Apoptosis due to inhibition of COX-2 is a result of shunting of AA metabolism to stimulate the production of ceramide, a mediator of apoptosis [<CitationRef CitationID="CR90_33">90</CitationRef>]. Thus, nonsteroidal anti-inflammatory agents (NSAIDs) or specific COX-2 inhibitors to inhibit COX-2 and PG synthesis may have therapeutic or chemopreventive potential (Fig. <InternalRef RefID="Fig2">33.2</InternalRef>). Studies using animal models of prostate carcinogenesis and metastasis demonstrated suppression of tumor growth and metastasis with nonsteroidal anti-inflammatory agents (NSAIDs) or selective COX-2 inhibitors [<CitationRef CitationID="CR91_33">91</CitationRef>, <CitationRef CitationID="CR92_33">92</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig2">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 33.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Schematic diagram highlighting prostaglandin E2 (PGE2) synthesis from arachidonic acid (AA). PGE2, interacting with G-protein coupled receptors, leads to increased angiogenesis through upregulation of VEGF. Inhibition of cyclooxygenase-2 (COX-2) by nonsteroidal anti-inflammatory drugs (NSAIDS) and/or selective COX-2 inhibitors inhibits angiogenesis and promotes apoptosis through channeling of AA through ceramide. <Emphasis Type="Italic">PGG2</Emphasis> prostaglandin G2; <Emphasis Type="Italic">PGH2</Emphasis> prostaglandin H2</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO2_33">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_33_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
                     </Para>
            </Section2>
            <Section2 ID="Sec17">
              <Heading>Inflammation in Metastasis</Heading>
              <Para TextBreak="No">The role of inflammation in metastasis is not very well defined. The observation that matrix metalloprotiens (MMPs) are produced by leukocytes present within tumors suggests that matrix remodeling in areas of chronic inflammation may promote cell motility and intravasation of tumor cells [<CitationRef CitationID="CR93_33">93</CitationRef>]. Induction of angiogenesis in regions of chronic inflammation may also promote tumor metastasis. Perhaps most damning in the implication of chronic inflammation and metastatic dissemination of cancer cells comes from a study on the regulation of the metastasis suppressor Maspin by I<Emphasis Type="Italic">κ</Emphasis>B kinase<Emphasis Type="Italic">α</Emphasis> (IKK<Emphasis Type="Italic">α</Emphasis>). IKK<Emphasis Type="Italic">α</Emphasis> is activated by receptor activator of NF-<Emphasis Type="Italic">κ</Emphasis>B ligand (RANKL), a cytokine produced by inflammatory cells. An inverse correlation was observed, both in a mouse model and human tissue, between IKK<Emphasis Type="Italic">α</Emphasis> activation and Maspin production, suggesting that RANKL produced by inflammatory cells associated with prostate tumors activates IKK<Emphasis Type="Italic">α</Emphasis> leading to downregulation of Maspin and enhancement of metastasis [<CitationRef CitationID="CR62_33">62</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec18">
            <Heading>Targeting Inflammation in the Management of Prostate Cancer</Heading>
            <Para TextBreak="No">When designing clinical trials targeting inflammation in prostate cancer, both the protumorigenic and antitumorigenic roles of inflammatory cells and processes must be considered. Strategies aimed at interfering with the above protumorigenic processes while bolstering antitumorigenic cell-mediated immunity would be ideal. For the latter, emerging evidence suggests that stimulating antitumor T-cell responses using aminobisphosphonates (activation of γ<Emphasis Type="Italic">δ</Emphasis> T cells) or stimulating hsp70 activity holds promise for treatment of advanced prostate cancer [<CitationRef CitationID="CR94_33">94</CitationRef>, <CitationRef CitationID="CR95_33">95</CitationRef>].</Para>
            <Para TextBreak="No">Coupling increased cell proliferation with mutagenesis forms the key recipe for carcinogenesis. Formation of new vasculature (angiogenesis) and stimulation of cell motility then sets the stage for tumor progression. As reviewed herein, factors produced by inflammatory cells may participate during all stages of carcinogenesis including early events of tumor initiation and promotion (Fig. <InternalRef RefID="Fig3">33.3</InternalRef>). Thus, key regulatory elements in the inflammatory response, such as NF-<Emphasis Type="Italic">κ</Emphasis>B and COX-2, represent legitimate targets for chemoprevention and therapeutic strategies. In support of this, a case–control study reported a 55% risk reduction for prostate cancer with selective COX-2 inhibitors after adjusting for age and potential confounders [<CitationRef CitationID="CR96_33">96</CitationRef>]. A meta-analysis of 91 epidemiologic studies showed significant risk reductions for a number of human malignancies, including a 39% risk reduction for prostate cancer in patients daily taking NSAIDS [<CitationRef CitationID="CR97_33">97</CitationRef>]. There was an inverse association between NSAID intake and prostate cancer risk. COX-2 inhibitors have also been used in clinical trials in men with rising PSA after radical prostatectomy and/or radiation therapy for prostate cancer. Although outcomes data have not been reported, use of COX-2 inhibitors slowed PSA doubling times, suggesting an effect on tumor progression [<CitationRef CitationID="CR98_33">98</CitationRef>, <CitationRef CitationID="CR99_33">99</CitationRef>]. Non-COX-2-dependent mechanisms may be responsible for some of the anticancer effects of these drugs [<CitationRef CitationID="CR100_33">100</CitationRef>]. To date, use of COX-2 inhibitors for chemoprevention is limited due to the potential for adverse cardiovascular effects; future refinement of these agents to minimize cardiovascular toxicity is warranted.<Figure Category="Standard" Float="Yes" ID="Fig3">
                <Caption Language="En">
                  <CaptionNumber>Fig. 33.3</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>The interplay between pro-inflammatory factors produced by prostatic epithelium during progression of prostatic carcinogenesis and reciprocal products of chronic inflammation. Following stimulation by one or more stimuli (<Emphasis Type="Italic">white cloud</Emphasis>), pro-inflammatory factors (<Emphasis Type="Italic">blue box</Emphasis> and <Emphasis Type="Italic">arrow</Emphasis>) stimulate production of protumorigenic cytokines and growth factors (<Emphasis Type="Italic">orange box</Emphasis> and <Emphasis Type="Italic">arrows</Emphasis>) and reactive oxygen/nitrogen species (ROS/RNS, <Emphasis Type="Italic">yellow box</Emphasis> and <Emphasis Type="Italic">arrows</Emphasis>) promoting progression of tumorigenesis through increased cell proliferation coupled with progressive DNA damage and angiogenesis. <Emphasis Type="Italic">PIA</Emphasis> proliferative inflammatory atrophy; <Emphasis Type="Italic">PIN</Emphasis> prostatic intraepithelial neoplasia</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO3_33">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_33_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
                  </Para>
            <Para TextBreak="No">Combating oxidative stress through the use of antioxidants is particularly attractive for chemoprevention since these agents are usually well tolerated, and intake can be increased through the diet by taking supplements. Antioxidants such as lycopene (tomato products), resveratrol (grape products, peanuts), selenium, and vitamin E are being evaluated clinically. The effect of these agents may involve other anticancer actions (e.g., cell cycle inhibition) in addition to antioxidant properties.</Para>
          </Section1>
          <Section1 ID="Sec19" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">As more is learned about the multiple pathways involved in carcinogenesis, newer targets for intervention will emerge. Eventually, we could envision combination strategies targeting many pathways simultaneously using pharmacological and dietary approaches. While rationale for control of inflammation is sound for chemoprevention, it may also be strong for adjuvant therapy. Since more conservative approaches toward the management of prostate cancer, including expectant management and targeted focal therapies, are being introduced, the role of anti-inflammatory/antioxidant agents for prostate cancer therapy must also be pursued.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_33.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_33">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kuper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HO</Initials>
                  <FamilyName>Adami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Trichopoulos</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Infections as a major preventable cause of human cancer</ArticleTitle>
                <JournalTitle>J Intern Med</JournalTitle>
                <VolumeID>248</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>171</FirstPage>
                <LastPage>183</LastPage>
                <Occurrence Type="PID">
                  <Handle>10971784</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3cvps1Cqtw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1365-2796.2000.00742.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248(3):171–183.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_33">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Bostwick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>de la</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Dundore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FA</Initials>
                  <FamilyName>Corica</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Iczkowski</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Intraepithelial and stromal lymphocytes in the normal human prostate</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>55</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>187</FirstPage>
                <LastPage>193</LastPage>
                <Occurrence Type="PID">
                  <Handle>12692784</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10224</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bostwick DG, de la RG, Dundore P, Corica FA, Iczkowski KA. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 2003; 55(3):187–193.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_33">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Theyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Kramer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Assmann</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>Lab Invest</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>96</FirstPage>
                <LastPage>107</LastPage>
                <Occurrence Type="PID">
                  <Handle>1370561</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387hsVGjsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Theyer G, Kramer G, Assmann I et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66(1):96–107.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_33">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Platz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Sutcliffe</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Inflammation in prostate carcinogenesis</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>256</FirstPage>
                <LastPage>269</LastPage>
                <Occurrence Type="PID">
                  <Handle>17384581</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc2090</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De Marzo AM, Platz EA, Sutcliffe S et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7(4):256–269.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_33">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Steiner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Gessl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Kramer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Schollhammer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Forster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Marberger</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>151</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>480</FirstPage>
                <LastPage>484</LastPage>
                <Occurrence Type="PID">
                  <Handle>7506795</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7htFagsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steiner G, Gessl A, Kramer G, Schollhammer A, Forster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994; 151(2):480–484.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_33">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Steiner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Stix</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Handisurya</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue</ArticleTitle>
                <JournalTitle>Lab Invest</JournalTitle>
                <VolumeID>83</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1131</FirstPage>
                <LastPage>1146</LastPage>
                <Occurrence Type="PID">
                  <Handle>12920242</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmtVentr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.LAB.0000081388.40145.65</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steiner GE, Stix U, Handisurya A et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83(8):1131–1146.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_33">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Steiner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Djavan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Kramer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">The picture of the prostatic lymphokine network is becoming increasingly complex</ArticleTitle>
                <JournalTitle>Rev Urol</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>171</FirstPage>
                <LastPage>177</LastPage>
                <Occurrence Type="PID">
                  <Handle>16985676</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steiner GE, Djavan B, Kramer G et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 2002; 4(4):171–177.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_33">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Steiner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Newman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Paikl</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>56</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>171</FirstPage>
                <LastPage>182</LastPage>
                <Occurrence Type="PID">
                  <Handle>12772186</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXntVWgu7w%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10238</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steiner GE, Newman ME, Paikl D et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56(3):171–182.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_33">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Groh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Rhinehart</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Secrist</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Grabstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Spies</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>6879</FirstPage>
                <LastPage>6884</LastPage>
                <Occurrence Type="PID">
                  <Handle>10359807</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXks1Wktro%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.96.12.6879</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999; 96(12):6879–6884.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_33">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Kramer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Mitteregger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Marberger</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1202</FirstPage>
                <LastPage>1216</LastPage>
                <Occurrence Type="PID">
                  <Handle>17182170</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmsFOksL0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2006.12.011</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51(5):1202–1216.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_33">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VL</Initials>
                  <FamilyName>Marchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>155</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1985</FirstPage>
                <LastPage>1992</LastPage>
                <Occurrence Type="PID">
                  <Handle>10595928</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)65517-4</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155(6):1985–1992.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_33">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Platz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A working group classification of focal prostate atrophy lesions</ArticleTitle>
                <JournalTitle>Am J Surg Pathol</JournalTitle>
                <VolumeID>30</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1281</FirstPage>
                <LastPage>1291</LastPage>
                <Occurrence Type="PID">
                  <Handle>17001160</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.pas.0000213289.50660.be</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De Marzo AM, Platz EA, Epstein JI et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006; 30(10):1281–1291.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_33">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakayama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Bennett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Hicks</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>163</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>923</FirstPage>
                <LastPage>933</LastPage>
                <Occurrence Type="PID">
                  <Handle>12937133</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXnsVCju74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)63452-9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nakayama M, Bennett CJ, Hicks JL et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003; 163(3):923–933.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_33">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Sutcliffe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Zenilman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KG</Initials>
                  <FamilyName>Ghanem</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>175</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1937</FirstPage>
                <LastPage>1942</LastPage>
                <Occurrence Type="PID">
                  <Handle>16600802</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)00892-X</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sutcliffe S, Zenilman JM, Ghanem KG et al. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 2006; 175(5):1937–1942.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_33">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LK</Initials>
                  <FamilyName>Dennis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DV</Initials>
                  <FamilyName>Dawson</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Meta-analysis of measures of sexual activity and prostate cancer</ArticleTitle>
                <JournalTitle>Epidemiology</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>72</FirstPage>
                <LastPage>79</LastPage>
                <Occurrence Type="PID">
                  <Handle>11805589</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00001648-200201000-00012</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13(1):72–79.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_33">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Mainous</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Wells</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Prostate cancer and sexually transmitted diseases: a meta-analysis</ArticleTitle>
                <JournalTitle>Fam Med</JournalTitle>
                <VolumeID>37</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>506</FirstPage>
                <LastPage>512</LastPage>
                <Occurrence Type="PID">
                  <Handle>15988645</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taylor ML, Mainous AG, III, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005; 37(7):506–512.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_33">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Sutcliffe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Alderete</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>939</FirstPage>
                <LastPage>945</LastPage>
                <Occurrence Type="PID">
                  <Handle>16702374</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XksFeiu78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-05-0781</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sutcliffe S, Giovannucci E, Alderete JF et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(5):939–945.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_33">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HD</Initials>
                  <FamilyName>Strickler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Goedert</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Sexual behavior and evidence for an infectious cause of prostate cancer</ArticleTitle>
                <JournalTitle>Epidemiol Rev</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>144</FirstPage>
                <LastPage>151</LastPage>
                <Occurrence Type="PID">
                  <Handle>11588840</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3Mrkt1Slug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/oxfordjournals.epirev.a000781</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001; 23(1):144–151.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_33">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Urisman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Molinaro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Fischer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant</ArticleTitle>
                <JournalTitle>PLoS Pathog</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>e25</FirstPage>
                <Occurrence Type="PID">
                  <Handle>16609730</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1371/journal.ppat.0020025</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Urisman A, Molinaro RJ, Fischer N et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2(3):e25.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_33">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Savage</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Vosseller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>319</VolumeID>
                <IssueID>5860</IssueID>
                <FirstPage>215</FirstPage>
                <LastPage>220</LastPage>
                <Occurrence Type="PID">
                  <Handle>18187659</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXis1alsA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1148886</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Savage PA, Vosseller K, Kang C et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008; 319(5860):215–220.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_33">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ponniah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Arah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Alexander</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>44</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>49</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861757</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCru7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0045(20000615)44:1&lt;49::AID-PROS7&gt;3.0.CO;2-7</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000; 44(1):49–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_33">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Molecular regulation of androgen action in prostate cancer</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>99</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>333</FirstPage>
                <LastPage>344</LastPage>
                <Occurrence Type="PID">
                  <Handle>16518832</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVSktL%2FE</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcb.20794</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99(2):333–344.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_33">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PL</Initials>
                  <FamilyName>Harkonen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SI</Initials>
                  <FamilyName>Makela</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Role of estrogens in development of prostate cancer</ArticleTitle>
                <JournalTitle>J Steroid Biochem Mol Biol</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>297</FirstPage>
                <LastPage>305</LastPage>
                <Occurrence Type="PID">
                  <Handle>15663993</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.jsbmb.2004.10.016</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004; 92(4):297–305.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_33">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Boileau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Bray</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Dietary influences on endocrine-inflammatory interactions in prostate cancer development</ArticleTitle>
                <JournalTitle>Arch Biochem Biophys</JournalTitle>
                <VolumeID>428</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>109</FirstPage>
                <LastPage>117</LastPage>
                <Occurrence Type="PID">
                  <Handle>15234275</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlsVartbc%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.abb.2004.01.009</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ho E, Boileau TW, Bray TM. Dietary influences on endocrine- inflammatory interactions in prostate cancer development. Arch Biochem Biophys 2004; 428(1):109–117.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_33">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature</ArticleTitle>
                <JournalTitle>J Nutr</JournalTitle>
                <VolumeID>135</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2030S</FirstPage>
                <LastPage>2031S</LastPage>
                <Occurrence Type="PID">
                  <Handle>16046732</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXps1yjurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005; 135(8):2030S–2031S.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_33">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OP</Initials>
                  <FamilyName>Heinonen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Albanes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Virtamo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>440</FirstPage>
                <LastPage>446</LastPage>
                <Occurrence Type="PID">
                  <Handle>9521168</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXitlejtbs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/90.6.440</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heinonen OP, Albanes D, Virtamo J et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90(6):440–446.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_33">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Duffield-Lillico</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Dalkin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>91</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>608</FirstPage>
                <LastPage>612</LastPage>
                <Occurrence Type="PID">
                  <Handle>12699469</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXks1ynu70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1464-410X.2003.04167.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Duffield-Lillico AJ, Dalkin BL, Reid ME et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91(7):608–612.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_33">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Knize</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Felton</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Formation and human risk of carcinogenic heterocyclic amines formed from natural precursors in meat</ArticleTitle>
                <JournalTitle>Nutr Rev</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>158</FirstPage>
                <LastPage>165</LastPage>
                <Occurrence Type="PID">
                  <Handle>15971410</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1753-4887.2005.tb00133.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Knize MG, Felton JS. Formation and human risk of carcinogenic heterocyclic amines formed from natural precursors in meat. Nutr Rev 2005; 63(5):158–165.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_33">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Nakai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1378</FirstPage>
                <LastPage>1384</LastPage>
                <Occurrence Type="PID">
                  <Handle>17264317</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1ynt7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-1336</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 2007; 67(3):1378–1384.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_33">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MF</Initials>
                  <FamilyName>Leitzmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Platz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Stampfer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Willett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Ejaculation frequency and subsequent risk of prostate cancer</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>291</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>1578</FirstPage>
                <LastPage>1586</LastPage>
                <Occurrence Type="PID">
                  <Handle>15069045</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjtVamsbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.291.13.1578</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Leitzmann MF, Platz EA, Stampfer MJ, Willett WC, Giovannucci E. Ejaculation frequency and subsequent risk of prostate cancer. JAMA 2004; 291(13):1578–1586.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_33">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lichtenstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NV</Initials>
                  <FamilyName>Holm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Verkasalo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>343</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>78</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>10891514</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3czjtFCiug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM200007133430201</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343(2):78–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_33">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WF</Initials>
                  <FamilyName>Page</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Braun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Partin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Caporaso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Heredity and prostate cancer: a study of World War II veteran twins</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>33</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>240</FirstPage>
                <LastPage>245</LastPage>
                <Occurrence Type="PID">
                  <Handle>9397195</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c%2FlvFentg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19971201)33:4&lt;240::AID-PROS3&gt;3.0.CO;2-L</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997; 33(4):240–245.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_33">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Gronberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Damber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Damber</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Studies of genetic factors in prostate cancer in a twin population</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>152</VolumeID>
                <IssueID>5 Pt 1</IssueID>
                <FirstPage>1484</FirstPage>
                <LastPage>1487</LastPage>
                <Occurrence Type="PID">
                  <Handle>7933190</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M%2FhvVOhtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152(5 Pt 1):1484–1487.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_33">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Freije</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Carpten</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>274</VolumeID>
                <IssueID>5291</IssueID>
                <FirstPage>1371</FirstPage>
                <LastPage>1374</LastPage>
                <Occurrence Type="PID">
                  <Handle>8910276</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XntFKlsr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.274.5291.1371</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274(5291):1371–1374.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_33">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lindmark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Wiklund</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>1248</FirstPage>
                <LastPage>1254</LastPage>
                <Occurrence Type="PID">
                  <Handle>15316060</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXntFamt78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djh227</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lindmark F, Zheng SL, Wiklund F et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96(16):1248–1254.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_33">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Komiya</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>32</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>321</FirstPage>
                <LastPage>325</LastPage>
                <Occurrence Type="PID">
                  <Handle>12244320</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xotlaisbs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng994</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xu J, Zheng SL, Komiya A et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32(2):321–325.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_33">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Turner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Gronberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Genetic variability in inflammation pathways and prostate cancer risk</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>250</FirstPage>
                <LastPage>259</LastPage>
                <Occurrence Type="PID">
                  <Handle>17483024</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXkvFGrurs%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2006.10.001</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sun J, Turner A, Xu J, Gronberg H, Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007; 25(3):250–259.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_33">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Castelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Hassel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Wood</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>186</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>967</FirstPage>
                <LastPage>972</LastPage>
                <Occurrence Type="PID">
                  <Handle>9294150</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmtV2itbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.186.6.967</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Castelli JC, Hassel BA, Wood KA et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 1997; 186(6):967–972.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_33">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Schaid</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The complex genetic epidemiology of prostate cancer</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>R103</FirstPage>
                <LastPage>R121</LastPage>
                <Occurrence Type="PID">
                  <Handle>14749351</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXivFCkurY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/ddh072</Handle>
                </Occurrence>
                <BibComments>Spec No 1</BibComments>
              </BibArticle>
              <BibUnstructured>Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 Spec No 1:R103–R121.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_33">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Bootcov</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Bauskin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Valenzuela</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>94</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>11514</FirstPage>
                <LastPage>11519</LastPage>
                <Occurrence Type="PID">
                  <Handle>9326641</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmslaqsr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.94.21.11514</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bootcov MR, Bauskin AR, Valenzuela SM et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997; 94(21):11514–11519.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_33">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Baek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nixon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TE</Initials>
                  <FamilyName>Eling</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>901</FirstPage>
                <LastPage>908</LastPage>
                <Occurrence Type="PID">
                  <Handle>11259636</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXisVSqsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59(4):901–908.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_33">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Tan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Guan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>97</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>109</FirstPage>
                <LastPage>114</LastPage>
                <Occurrence Type="PID">
                  <Handle>10618379</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjvVCkug%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.97.1.109</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000; 97(1):109–114.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_33">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VM</Initials>
                  <FamilyName>Paralkar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Vail</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WA</Initials>
                  <FamilyName>Grasser</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>273</VolumeID>
                <IssueID>22</IssueID>
                <FirstPage>13760</FirstPage>
                <LastPage>13767</LastPage>
                <Occurrence Type="PID">
                  <Handle>9593718</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjvVejur8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.273.22.13760</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Paralkar VM, Vail AL, Grasser WA et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998; 273(22):13760–13767.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_33">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Shim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TE</Initials>
                  <FamilyName>Eling</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>280</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>18636</FirstPage>
                <LastPage>18642</LastPage>
                <Occurrence Type="PID">
                  <Handle>15757899</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjvFekt7g%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M414613200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 2005; 280(19):18636–18642.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_33">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Fairlie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Bauskin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HP</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Breit</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation</ArticleTitle>
                <JournalTitle>J Leukoc Biol</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>2</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9886240</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1yqsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999; 65(1):2–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_33">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VM</Initials>
                  <FamilyName>Hayes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Severi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Southey</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1223</FirstPage>
                <LastPage>1225</LastPage>
                <Occurrence Type="PID">
                  <Handle>16775185</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xls1ehtr4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-06-0063</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hayes VM, Severi G, Southey MC et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006; 15(6):1223–1225.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_33">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Gough</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Greaves</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Gordon</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake</ArticleTitle>
                <JournalTitle>J Lipid Res</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>531</FirstPage>
                <LastPage>543</LastPage>
                <Occurrence Type="PID">
                  <Handle>9548586</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXit1Kmtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gough PJ, Greaves DR, Gordon S. A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake. J Lipid Res 1998; 39(3):531–543.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_33">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Peiser</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Winther</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Makepeace</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses</ArticleTitle>
                <JournalTitle>Infect Immun</JournalTitle>
                <VolumeID>70</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>5346</FirstPage>
                <LastPage>5354</LastPage>
                <Occurrence Type="PID">
                  <Handle>12228258</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XnsV2mu7Y%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/IAI.70.10.5346-5354.2002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peiser L, De Winther MP, Makepeace K et al. The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect Immun 2002; 70(10):5346–5354.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_33">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FC</Initials>
                  <FamilyName>Hsu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Turner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>728</FirstPage>
                <LastPage>737</LastPage>
                <Occurrence Type="PID">
                  <Handle>16425212</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkslWitLw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20396</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sun J, Hsu FC, Turner AR et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006; 66(7):728–737.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_33">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Alexander</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ponniah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hasday</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Hebel</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>52</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>744</FirstPage>
                <LastPage>749</LastPage>
                <Occurrence Type="PID">
                  <Handle>9801092</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M%2FhsFOisw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(98)00390-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Alexander RB, Ponniah S, Hasday J, Hebel JR. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 1998; 52(5):744–749.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_33">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Uehara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Karashima</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mccarty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Shih</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IJ</Initials>
                  <FamilyName>Fidler</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice</ArticleTitle>
                <JournalTitle>Neoplasia</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>33</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>11326314</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXis1agu7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.neo.7900124</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kim SJ, Uehara H, Karashima T, Mccarty M, Shih N, Fidler IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001; 3(1):33–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_33">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Augustsson-Balter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2918</FirstPage>
                <LastPage>2922</LastPage>
                <Occurrence Type="PID">
                  <Handle>15087412</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjtV2lurg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-03-3280</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zheng SL, ugustsson-Balter K, Chang B et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64(8):2918–2922.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_33">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Wiklund</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>97</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>525</FirstPage>
                <LastPage>532</LastPage>
                <Occurrence Type="PID">
                  <Handle>15812078</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjtFaltrY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/dji070</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sun J, Wiklund F, Zheng SL et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97(7):525–532.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_33">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FM</Initials>
                  <FamilyName>Burnet</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Immunological surveillance in neoplasia</ArticleTitle>
                <JournalTitle>Transplant Rev</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>3</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>5146537</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE387msVaqsA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1600-065X.1971.tb00461.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7:3–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_33">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Langowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">IL-23 promotes tumour incidence and growth</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>442</VolumeID>
                <IssueID>7101</IssueID>
                <FirstPage>461</FirstPage>
                <LastPage>465</LastPage>
                <Occurrence Type="PID">
                  <Handle>16688182</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnsVajtbk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature04808</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442(7101):461–465.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_33">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>O’Byrne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Dalgleish</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Chronic immune activation and inflammation as the cause of malignancy</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>473</FirstPage>
                <LastPage>483</LastPage>
                <Occurrence Type="PID">
                  <Handle>11506482</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1054/bjoc.2001.1943</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85(4):473–483.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_33">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Balkwill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mantovani</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Inflammation and cancer: back to Virchow?</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>357</VolumeID>
                <IssueID>9255</IssueID>
                <FirstPage>539</FirstPage>
                <LastPage>545</LastPage>
                <Occurrence Type="PID">
                  <Handle>11229684</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXhsVKltb0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(00)04046-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357(9255):539–545.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_33">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Beutler</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The role of tumor necrosis factor in health and disease</ArticleTitle>
                <JournalTitle>J Rheumatol Suppl</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>16</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>10328138</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjtFyku78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 1999; 57:16–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_33">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mizokami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Gotoh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Yamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Matsumoto</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>164</VolumeID>
                <IssueID>3 Pt 1</IssueID>
                <FirstPage>800</FirstPage>
                <LastPage>805</LastPage>
                <Occurrence Type="PID">
                  <Handle>10953159</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmtlSmsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000; 164(3 Pt 1):800–805.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_33">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Verma</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">NF-kappaB regulation in the immune system</ArticleTitle>
                <JournalTitle>Nat Rev Immunol</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>725</FirstPage>
                <LastPage>734</LastPage>
                <Occurrence Type="PID">
                  <Handle>12360211</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XnsVGqsbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nri910</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2(10):725–734.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_33">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Naugler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Karin</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">NF-kappaB and cancer-identifying targets and mechanisms</ArticleTitle>
                <JournalTitle>Curr Opin Genet Dev</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>19</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>18440219</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmsVartb4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.gde.2008.01.020</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18(1):19–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_33">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Tan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Ricono</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>446</VolumeID>
                <IssueID>7136</IssueID>
                <FirstPage>690</FirstPage>
                <LastPage>694</LastPage>
                <Occurrence Type="PID">
                  <Handle>17377533</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjslOlsLk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature05656</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Luo JL, Tan W, Ricono JM et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446(7136):690–694.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_33">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EC</Initials>
                  <FamilyName>Breen</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">VEGF in biological control</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>102</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1358</FirstPage>
                <LastPage>1367</LastPage>
                <Occurrence Type="PID">
                  <Handle>17979153</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhsVeit7fE</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcb.21579</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Breen EC. VEGF in biological control. J Cell Biochem 2007; 102(6):1358–1367.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_33">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Aita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Fasola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Defferrari</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer</ArticleTitle>
                <JournalTitle>Crit Rev Oncol Hematol</JournalTitle>
                <VolumeID>68</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>183</FirstPage>
                <LastPage>196</LastPage>
                <Occurrence Type="PID">
                  <Handle>18606548</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.critrevonc.2008.05.002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aita M, Fasola G, Defferrari C et al. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008; 68(3):183–196.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_33">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kollermann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Helpap</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue</ArticleTitle>
                <JournalTitle>Am J Clin Pathol</JournalTitle>
                <VolumeID>116</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>115</FirstPage>
                <LastPage>121</LastPage>
                <Occurrence Type="PID">
                  <Handle>11447740</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXltlKgtbY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1309/1LBM-6X32-JH6W-ENUD</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001; 116(1):115–121.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_33">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Ito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Kitadai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kyo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>4102</FirstPage>
                <LastPage>4106</LastPage>
                <Occurrence Type="PID">
                  <Handle>8358739</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXmsVWqur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ito R, Kitadai Y, Kyo E et al. Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res 1993; 53(17):4102–4106.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_33">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bar-Eli</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Role of interleukin-8 in tumor growth and metastasis of human melanoma</ArticleTitle>
                <JournalTitle>Pathobiology</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>12</FirstPage>
                <LastPage>18</LastPage>
                <Occurrence Type="PID">
                  <Handle>9873223</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXnvVyjtQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000028045</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999; 67(1):12–18.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_33">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Brigati</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Noonan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Albini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Benelli</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Tumors and inflammatory infiltrates: friends or foes?</ArticleTitle>
                <JournalTitle>Clin Exp Metastasis</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>247</FirstPage>
                <LastPage>258</LastPage>
                <Occurrence Type="PID">
                  <Handle>12067205</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XltFSgu7k%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1023/A:1015587423262</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002; 19(3):247–258.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_33">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Xie</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Interleukin-8 and human cancer biology</ArticleTitle>
                <JournalTitle>Cytokine Growth Factor Rev</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>375</FirstPage>
                <LastPage>391</LastPage>
                <Occurrence Type="PID">
                  <Handle>11544106</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmsFChtLg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1359-6101(01)00016-8</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12(4):375–391.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_33">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Coussens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Werb</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Inflammation and cancer</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>420</VolumeID>
                <IssueID>6917</IssueID>
                <FirstPage>860</FirstPage>
                <LastPage>867</LastPage>
                <Occurrence Type="PID">
                  <Handle>12490959</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XpsFygtb4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature01322</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917):860–867.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_33">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BB</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Arenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Stoy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>154</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1503</FirstPage>
                <LastPage>1512</LastPage>
                <Occurrence Type="PID">
                  <Handle>10329603</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjtl2hsr8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)65404-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moore BB, Arenberg DA, Stoy K et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999; 154(5):1503–1512.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_33">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Parsons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Gage</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Kensler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>49</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>30</FirstPage>
                <LastPage>37</LastPage>
                <Occurrence Type="PID">
                  <Handle>11550208</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MrgtVOlsA%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.1115</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 2001; 49(1):30–37.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_33">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kovacic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Jacintho</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer</ArticleTitle>
                <JournalTitle>Curr Med Chem</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>773</FirstPage>
                <LastPage>796</LastPage>
                <Occurrence Type="PID">
                  <Handle>11375749</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsVChtbY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2174/0929867013373084</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kovacic P, Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 2001; 8(7):773–796.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_33">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Ohshima</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Nitrative DNA damage in inflammation and its possible role in carcinogenesis</ArticleTitle>
                <JournalTitle>Nitric Oxide</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>91</FirstPage>
                <LastPage>100</LastPage>
                <Occurrence Type="PID">
                  <Handle>16099698</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFWgtLY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.niox.2005.06.005</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sawa T, Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 2006; 14(2):91–100.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_33">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Zidek</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Role of cytokines in the modulation of nitric oxide production by cyclic AMP</ArticleTitle>
                <JournalTitle>Eur Cytokine Netw</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>22</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>11282542</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXivFGltL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zidek Z. Role of cytokines in the modulation of nitric oxide production by cyclic AMP. Eur Cytokine Netw 2001; 12(1):22–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_33">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Shen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Hazen</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Activated leukocytes oxidatively damage DNA, RNA, and the nucleotide pool through halide-dependent formation of hydroxyl radical</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>39</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>5474</FirstPage>
                <LastPage>5482</LastPage>
                <Occurrence Type="PID">
                  <Handle>10820020</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXitlylsbg%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/bi992809y</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shen Z, Wu W, Hazen SL. Activated leukocytes oxidatively damage DNA, RNA, and the nucleotide pool through halide-dependent formation of hydroxyl radical. Biochemistry 2000; 39(18):5474–5482.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_33">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Hayes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Pulford</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance</ArticleTitle>
                <JournalTitle>Crit Rev Biochem Mol Biol</JournalTitle>
                <VolumeID>30</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>445</FirstPage>
                <LastPage>600</LastPage>
                <Occurrence Type="PID">
                  <Handle>8770536</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhtFGks7s%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3109/10409239509083491</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30(6):445–600.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_33">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Deweese</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>57</VolumeID>
                <IssueID>4 Suppl 1</IssueID>
                <FirstPage>39</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>11295593</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M3msF2htQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(00)00939-0</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson WG, De Marzo AM, Deweese TL. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 2001; 57(4 Suppl 1):39–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_33">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Bostwick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EE</Initials>
                  <FamilyName>Alexander</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>123</FirstPage>
                <LastPage>134</LastPage>
                <Occurrence Type="PID">
                  <Handle>10897009</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXltFKktrw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20000701)89:1&lt;123::AID-CNCR17&gt;3.0.CO;2-9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bostwick DG, Alexander EE, Singh R et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89(1):123–134.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_33">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MO</Initials>
                  <FamilyName>Ripple</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WF</Initials>
                  <FamilyName>Henry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>Rago</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>40</FirstPage>
                <LastPage>48</LastPage>
                <Occurrence Type="PID">
                  <Handle>8978405</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjvVamsg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/89.1.40</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997; 89(1):40–48.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_33">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Hirst</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Robson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Nitrosative stress in cancer therapy</ArticleTitle>
                <JournalTitle>Front Biosci</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>3406</FirstPage>
                <LastPage>3418</LastPage>
                <Occurrence Type="PID">
                  <Handle>17485309</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXms1KmtL4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2741/2322</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hirst DG, Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007; 12:3406–3418.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_33">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Jackson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Loeb</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The contribution of endogenous sources of DNA damage to the multiple mutations in cancer</ArticleTitle>
                <JournalTitle>Mutat Res</JournalTitle>
                <VolumeID>477</VolumeID>
                <IssueID>1–2</IssueID>
                <FirstPage>7</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>11376682</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjslenu7s%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0027-5107(01)00091-4</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001; 477(1–2):7–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_33">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Uchida</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress</ArticleTitle>
                <JournalTitle>Mol Cells</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>347</FirstPage>
                <LastPage>351</LastPage>
                <Occurrence Type="PID">
                  <Handle>18483467</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXntFart78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Uchida K. A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress. Mol Cells 2008; 25(3):347–351.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_33">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Wahl</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>175</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>5423</FirstPage>
                <LastPage>5429</LastPage>
                <Occurrence Type="PID">
                  <Handle>16210649</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVyltr7K</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005; 175(8):5423–5429.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_33">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Fosslien</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Molecular pathology of cyclooxygenase-2 in neoplasia</ArticleTitle>
                <JournalTitle>Ann Clin Lab Sci</JournalTitle>
                <VolumeID>30</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>3</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>10678579</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXht1altr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30(1):3–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_33">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Cao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Prescott</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Many actions of cyclooxygenase-2 in cellular dynamics and in cancer</ArticleTitle>
                <JournalTitle>J Cell Physiol</JournalTitle>
                <VolumeID>190</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>279</FirstPage>
                <LastPage>286</LastPage>
                <Occurrence Type="PID">
                  <Handle>11857443</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhtV2hu7g%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcp.10068</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190(3):279–286.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_33">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Gately</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WW</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>31</VolumeID>
                <IssueID>2 Suppl 7</IssueID>
                <FirstPage>2</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>15179620</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXls1Oltbo%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1053/j.seminoncol.2004.03.040</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31(2 Suppl 7):2–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_33">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Zha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Gage</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Sauvageot</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>24</IssueID>
                <FirstPage>8617</FirstPage>
                <LastPage>8623</LastPage>
                <Occurrence Type="PID">
                  <Handle>11751373</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xht1Ohtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61(24):8617–8623.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_33">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kirschenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Levine</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The role of cyclooxygenase-2 in prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>2 Suppl 1</IssueID>
                <FirstPage>127</FirstPage>
                <LastPage>131</LastPage>
                <Occurrence Type="PID">
                  <Handle>11502467</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3Mvlslehtg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(01)01255-9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58(2 Suppl 1):127–131.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_33">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Shao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Morrow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RD</Initials>
                  <FamilyName>Beauchamp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RN</Initials>
                  <FamilyName>DuBois</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>362</FirstPage>
                <LastPage>366</LastPage>
                <Occurrence Type="PID">
                  <Handle>9443418</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnt1altQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58(2):362–366.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_33">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Narayanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NK</Initials>
                  <FamilyName>Narayanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Pittman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BS</Initials>
                  <FamilyName>Reddy</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>22</IssueID>
                <FirstPage>7727</FirstPage>
                <LastPage>7737</LastPage>
                <Occurrence Type="PID">
                  <Handle>15570007</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVanur3L</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-0732</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10(22):7727–7737.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_33">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Narayanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NK</Initials>
                  <FamilyName>Narayanan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Pttman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BS</Initials>
                  <FamilyName>Reddy</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>257</FirstPage>
                <LastPage>265</LastPage>
                <Occurrence Type="PID">
                  <Handle>16175586</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XitVCnu78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20331</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006; 66(3):257–265.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_33">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NT</Initials>
                  <FamilyName>Le</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Xue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Castelnoble</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Jackson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">The dual personalities of matrix metalloproteinases in inflammation</ArticleTitle>
                <JournalTitle>Front Biosci</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>1475</FirstPage>
                <LastPage>1487</LastPage>
                <Occurrence Type="PID">
                  <Handle>17127395</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xht1WgsbzK</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2741/2161</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Le NT, Xue M, Castelnoble LA, Jackson CJ. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci 2007; 12:1475–1487.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_33">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Dieli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Vermijlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Fulfaro</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>7450</FirstPage>
                <LastPage>7457</LastPage>
                <Occurrence Type="PID">
                  <Handle>17671215</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXosVemtLY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-0199</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dieli F, Vermijlen D, Fulfaro F et al. Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67(15):7450–7457.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_33">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kottke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Sanchez-Perez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Diaz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>24</IssueID>
                <FirstPage>11970</FirstPage>
                <LastPage>11979</LastPage>
                <Occurrence Type="PID">
                  <Handle>18089828</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhsVCjs7bO</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-2259</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kottke T, Sanchez-Perez L, Diaz RM et al. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 2007; 67(24):11970–11979.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_33">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Beebe-Donk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Alshafie</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies</ArticleTitle>
                <JournalTitle>Subcell Biochem</JournalTitle>
                <VolumeID>42</VolumeID>
                <FirstPage>193</FirstPage>
                <LastPage>212</LastPage>
                <Occurrence Type="PID">
                  <Handle>17612052</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/1-4020-5688-5_9</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007; 42:193–212.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_33">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Beebe-Donk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Doss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Burr</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review)</ArticleTitle>
                <JournalTitle>Oncol Rep</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>559</FirstPage>
                <LastPage>583</LastPage>
                <Occurrence Type="PID">
                  <Handle>15756426</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjtFans74%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.3892/or.13.4.559</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Harris RE, Beebe-Donk J, Doss H, Burr DD. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13(4):559–583.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_33">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>2723</FirstPage>
                <LastPage>2728</LastPage>
                <Occurrence Type="PID">
                  <Handle>16782912</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntV2hu74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.03.7804</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24(18):2723–2728.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_33">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Pruthi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Derksen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>7 Pt 1</IssueID>
                <FirstPage>2172</FirstPage>
                <LastPage>2177</LastPage>
                <Occurrence Type="PID">
                  <Handle>16609031</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtlChs70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-2067</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pruthi RS, Derksen JE, Moore D et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12(7 Pt 1):2172–2177.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_33">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Sooriakumaran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Langley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Laing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Coley</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">COX-2 inhibition: a possible role in the management of prostate cancer?</ArticleTitle>
                <JournalTitle>J Chemother</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>21</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>17309847</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXislSgsro%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1179/joc.2007.19.1.21</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sooriakumaran P, Langley SE, Laing RW, Coley HM. COX-2 inhibition: a possible role in the management of prostate cancer? J Chemother 2007; 19(1):21–32.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
